GILEAD - After HIV -Poised to Deliver the Best Anti-Viral Treatment Options for HCV!
Gilead’s supremacy in the HIV space in 2012-18 should remain intact with the successful launch of Complera/Eviplera and Quad Pill. At EASL ‘12, impressive data from ELECTRON and QUANTUM study of GS-7977+RBV (PhII, HCV) promises of a possibility of GT1 pts to be cured with a 12-week treatment of GS-7977 (QD) and ribavirin. GS-7977 in combination with BMY’s daclatasvir (NS5A inhibitor, PhII) showed 100% of SVR4 and GILD has an option to take future development with own NS5A inhibitor. GILD’s other acquisition have started yielding results with couple of compounds reaching in to mid to late stages of clinical development…… For more detail, please read our report released on 3rd May, 2012 on Gilead titled “After HIV -Poised to Deliver the Best Anti-Viral Treatment Options for HCV!”
COMPANIES MENTIONED
GILEAD
GILEAD
